Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Hero Section Background Image

Sparsentan Clinical Trials in IgA Nephropathy

Sparsentan is a Dual Endothelin Angiotensin Receptor Antagonist (DEARA) indicated to slow kidney function decline in adults with primary IgA nephropathy who are at risk for disease progression1

Read full prescribing information, including boxed warning, here

PROTECT

Study design: PROTECT is a Phase 3, international, randomized, double-blind, active-controlled study of sparsentan vs. maximum-labeled dose irbesartan in adult patients with IgA nephropathy2

Objective: To evaluate long-term efficacy and safety in patients with biopsy-proven primary IgA nephropathy on maximum tolerated (stable) dose of RASi therapy for ≥12 weeks2

Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephropathy (PROTECT): 2-Year Results From a Randomised Active-Controlled Phase 3 Trial
IgAN

Rovin BH et al. The Lancet. 2023

PROTECT: Two-Year Efficacy and Safety Results

Read summary
Effects of Sparsentan after Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients with IgA Nephropathy (IgAN) in the PROTECT Trial 
IgAN

Floege J et al. Poster presented at: ERA 2025

PROTECT: Open-Label Extension

Read summary
Association Between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy
IgAN

Heerspink HJL et al. CJASN. 2025

PROTECT: Post Hoc Analysis of Complete Proteinuria Remission and Kidney Function

Read summary
PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 mo vs >12 mo From Kidney Biopsy
IgAN

Wadhwani S et al. Presentation at: ASN 2025

PROTECT: Post Hoc Analysis of Time From Kidney Biopsy

Read summary
Impact of Histology on Efficacy of Sparsentan Therapy in IgA Nephropathy: Central Biopsy Review of Patients in the PROTECT Trial
IgAN

Roberts I et al. Presentation at: ASN 2025

PROTECT: Histology and Central Biopsy Review

View presentation
PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g/g
IgAN

Kooienga L et al. Presentation at: ASN 2024

PROTECT: Subgroup Analysis of Proteinuria Above and Below 1 g/g

Read summary
Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
IgAN

Kooienga L et al.
Poster presented at: ASN 2024

PROTECT: Open-Label Extension SGLT2i Subgroup Analysis

Read summary

SPARTAN

Study design: SPARTAN is a Phase 2, open-label, single-arm, multicenter study in adult patients with IgA nephropathy3

Objective: To evaluate safety, efficacy, and biomarker findings in newly diagnosed treatment-naïve patients with IgA nephropathy3

Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy: An Interim Analysis of the SPARTAN Trial Evaluating Efficacy and Cardiovascular Risk Variables
IgAN

Cheung CK et al. Presentation at:
IIgANN 2025

SPARTAN: Cardiovascular Safety Interim Analysis

Read summary
Urinary Biomarker Analysis Reveals Rapid Intrarenal Anti‑inflammatory and Anti-fibrotic Effects of Sparsentan in IgA Nephropathy in the SPARTAN Study 
IgAN

Cheung CK et al. Presentation at: Podocyte ISGD 2025

SPARTAN: Urinary Biomarkers Interim Analysis

Read summary
Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy (IgAN): Interim Analysis of the SPARTAN Trial
IgAN

Cheung CK et al. Presentation at: ASN 2024

SPARTAN: Interim Safety and Efficacy Analysis

Read summary

SPARTACUS

Study design: Spartacus is a Phase 2, exploratory, open-label, single-arm, multicenter study of sparsentan when added to a stable SGLT2i in patients with IgA nephropathy at risk for disease progression4

Objective: To evaluate efficacy and safety in patients on concomitant sparsentan and SGLT2i treatment4

Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial
IgAN

Ayoub I et al. Presentation at: ERA 2025

SPARTACUS: Efficacy and Safety Results

Read summary
MSL CTA Image

Connect with our MSL team today

Arrange a meeting with a member of our medical science liaison (MSL) team to discuss the latest insights, clinical trial data, and management trends.

Find your MSL
Footnotes

IgA, immunoglobulin A; IgAN, IgA nephropathy; RASi, renin-angiotensin system inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor.

  1. FILSPARI® (sparsentan) Prescribing Information. San Diego, CA: Travere Therapeutics, Inc.
  2. Rovin BH et al. The Lancet. 2023;402:2077-2090.
  3. Cheung CK et al. Presented at: The American Society of Nephrology (ASN) Kidney Week 2024. October 23-27, 2024. San Diego, CA, USA. FR-OR63.
  4. Ayoub I et al. Presented at: GlomCon Hawaii 2025. September 22-25, 2025. Kahuku, HI, USA. Abstract 1049.

MA-DS-26-0034 | May 2026